|Bid||0.1450 x 2640300|
|Ask||0.1500 x 16362900|
|Day's range||0.1400 - 0.1500|
|52-week range||0.0924 - 0.4481|
|Beta (5Y monthly)||2.84|
|PE ratio (TTM)||N/A|
|Earnings date||25 Aug 2021|
|Forward dividend & yield||N/A (N/A)|
|1y target est||0.92|
Bionomics Limited (ASX: BNO, OTCQB:BNOEF) (Bionomics or Company), a clinical-stage biopharmaceutical company, is pleased to announce that as part of its broader pipeline expansion strategy and based on anti-anxiety signals in Generalised Anxiety Disorder (GAD) patients, it has decided to proceed with evaluating its lead clinical compound, BNC210, for acute treatment of Social Anxiety Disorder (SAD) with a planned commencement of a clinical trial by the end of this year.
Bionomics Limited ( ASX:BNO ) shareholders should be happy to see the share price up 27% in the last month. But that is...
Bionomics Limited (ASX: BNO, OTCQB: BNOEF), (Bionomics) a global, clinical stage biopharmaceutical company, is pleased to announce that it plans to conduct a registered initial public offering of American Depositary Shares (ADSs) in the United States and a concurrent listing of ADSs on Nasdaq. The number of ADSs and price of the proposed offering have not yet been determined. The proposed offering is expected to commence after the U.S. Securities and Exchange Commission completes its review proc